Cargando…
Unusual Presentation of Leukemic-Phase Mantle Cell Lymphoma: A Case Report
Mantle cell lymphoma (MCL) is a rare subtype of B-cell lymphoma that can present in a variety of ways, including the leukemic phase, where it can occasionally be mistaken for acute leukemia due to the unusually high or rapidly growing number of leukocytes and the presence of circulating cancer cells...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806947/ https://www.ncbi.nlm.nih.gov/pubmed/36601362 http://dx.doi.org/10.7759/cureus.33239 |
_version_ | 1784862619956412416 |
---|---|
author | Alsaati, Alshaimaa M Alasiri, Meshal M Alansari, Bayan A Mulla, Wed Y Al-Marzouki, Adel F Daous, Yara M Radhwi, Osman |
author_facet | Alsaati, Alshaimaa M Alasiri, Meshal M Alansari, Bayan A Mulla, Wed Y Al-Marzouki, Adel F Daous, Yara M Radhwi, Osman |
author_sort | Alsaati, Alshaimaa M |
collection | PubMed |
description | Mantle cell lymphoma (MCL) is a rare subtype of B-cell lymphoma that can present in a variety of ways, including the leukemic phase, where it can occasionally be mistaken for acute leukemia due to the unusually high or rapidly growing number of leukocytes and the presence of circulating cancer cells that are morphologically similar to leukemic blasts in myeloid or acute lymphoblastic leukemia. We present the case of an 83-year-old Yemeni woman with multiple comorbidities who presented with abdominal pain and constitutional symptoms. She was found to have diffuse lymphadenopathy on clinical and radiological assessments. Her white blood cell count at presentation was 221 × 10(9)/L with marked monocytosis (72.8%). Lymph node biopsy and bone marrow studies, including CCND1/IGH molecular studies, confirmed MCL, the pleomorphic subtype. The patient was deemed unfit for standard-of-care chemotherapy and was started on single-agent rituximab with a slow introduction to ibrutinib but succumbed to death after two weeks of ibrutinib 280 mg daily. This case serves as a reminder to keep an open mind and take into account atypical disease presentations when formulating differential diagnoses to prevent late diagnosis and any unnecessary intervention that can postpone appropriate therapy. |
format | Online Article Text |
id | pubmed-9806947 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-98069472023-01-03 Unusual Presentation of Leukemic-Phase Mantle Cell Lymphoma: A Case Report Alsaati, Alshaimaa M Alasiri, Meshal M Alansari, Bayan A Mulla, Wed Y Al-Marzouki, Adel F Daous, Yara M Radhwi, Osman Cureus Pathology Mantle cell lymphoma (MCL) is a rare subtype of B-cell lymphoma that can present in a variety of ways, including the leukemic phase, where it can occasionally be mistaken for acute leukemia due to the unusually high or rapidly growing number of leukocytes and the presence of circulating cancer cells that are morphologically similar to leukemic blasts in myeloid or acute lymphoblastic leukemia. We present the case of an 83-year-old Yemeni woman with multiple comorbidities who presented with abdominal pain and constitutional symptoms. She was found to have diffuse lymphadenopathy on clinical and radiological assessments. Her white blood cell count at presentation was 221 × 10(9)/L with marked monocytosis (72.8%). Lymph node biopsy and bone marrow studies, including CCND1/IGH molecular studies, confirmed MCL, the pleomorphic subtype. The patient was deemed unfit for standard-of-care chemotherapy and was started on single-agent rituximab with a slow introduction to ibrutinib but succumbed to death after two weeks of ibrutinib 280 mg daily. This case serves as a reminder to keep an open mind and take into account atypical disease presentations when formulating differential diagnoses to prevent late diagnosis and any unnecessary intervention that can postpone appropriate therapy. Cureus 2023-01-02 /pmc/articles/PMC9806947/ /pubmed/36601362 http://dx.doi.org/10.7759/cureus.33239 Text en Copyright © 2023, Alsaati et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Pathology Alsaati, Alshaimaa M Alasiri, Meshal M Alansari, Bayan A Mulla, Wed Y Al-Marzouki, Adel F Daous, Yara M Radhwi, Osman Unusual Presentation of Leukemic-Phase Mantle Cell Lymphoma: A Case Report |
title | Unusual Presentation of Leukemic-Phase Mantle Cell Lymphoma: A Case Report |
title_full | Unusual Presentation of Leukemic-Phase Mantle Cell Lymphoma: A Case Report |
title_fullStr | Unusual Presentation of Leukemic-Phase Mantle Cell Lymphoma: A Case Report |
title_full_unstemmed | Unusual Presentation of Leukemic-Phase Mantle Cell Lymphoma: A Case Report |
title_short | Unusual Presentation of Leukemic-Phase Mantle Cell Lymphoma: A Case Report |
title_sort | unusual presentation of leukemic-phase mantle cell lymphoma: a case report |
topic | Pathology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806947/ https://www.ncbi.nlm.nih.gov/pubmed/36601362 http://dx.doi.org/10.7759/cureus.33239 |
work_keys_str_mv | AT alsaatialshaimaam unusualpresentationofleukemicphasemantlecelllymphomaacasereport AT alasirimeshalm unusualpresentationofleukemicphasemantlecelllymphomaacasereport AT alansaribayana unusualpresentationofleukemicphasemantlecelllymphomaacasereport AT mullawedy unusualpresentationofleukemicphasemantlecelllymphomaacasereport AT almarzoukiadelf unusualpresentationofleukemicphasemantlecelllymphomaacasereport AT daousyaram unusualpresentationofleukemicphasemantlecelllymphomaacasereport AT radhwiosman unusualpresentationofleukemicphasemantlecelllymphomaacasereport |